Psoriasis Pipeline Assessment, 2023 Updates: FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, and Therapeutic Analysis | Amgen, AbbVie, Alumis, DICE Therapeutics, UCB Pharma, Janssen

 Breaking News
  • No posts were found

Psoriasis Pipeline Assessment, 2023 Updates: FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, and Therapeutic Analysis | Amgen, AbbVie, Alumis, DICE Therapeutics, UCB Pharma, Janssen

December 04
11:55 2023
Psoriasis Pipeline Assessment, 2023 Updates: FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, and Therapeutic Analysis | Amgen, AbbVie, Alumis, DICE Therapeutics, UCB Pharma, Janssen
(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Psoriasis pipeline constitutes 80+ key companies continuously working towards developing 80+ Psoriasis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Psoriasis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Psoriasis Pipeline Insight, 2023 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Psoriasis Market.

 

Some of the key takeaways from the Psoriasis Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Psoriasis treatment therapies with a considerable amount of success over the years. 
  • Psoriasis companies working in the treatment market are Fresh Tracks Therapeutics, Inmagene, SFA Therapeutics, Palobiofarma, Sun Pharmaceutical, Biohaven Pharmaceuticals, Inc., Dr. Reddy’s, MetrioPharm, Celltrion, Amgen, Can-Fite Biopharma, and others, are developing therapies for the Psoriasis treatment 
  • Emerging Psoriasis therapies in the different phases of clinical trials are- FRTX-03, IMG-008, SFA 002, PBF-1650, SCD-044, Rimegepant, PPC-06, MP1032, CT-P43, ABP 654, Piclidenoson, and others are expected to have a significant impact on the Psoriasis market in the coming years.   
  • In January 2023, SFA Therapeutics disclosed that the US FDA approved an extension for the ongoing Phase Ib clinical trial of SFA-002 targeting psoriasis. The trial’s anticipated completion is set for September 2023.
  • In April 2023, Can-Fite BioPharma revealed receiving a favorable opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) regarding the submission of a registration plan for a pivotal Phase III clinical trial. This trial aims to address the treatment of moderate to severe psoriasis. The agency has accepted the pivotal Phase III study and approved the safety evaluation for the 3 mg twice-daily dose of Piclidenoson.
  • In July 2022, Arcutis Biotherapeutics, Inc. obtained approval from the United States Food and Drug Administration (FDA) for the New Drug Application (NDA) of ZORYVE (roflumilast) cream 0.3%. This approval extends to treat plaque psoriasis, encompassing intertriginous areas, in patients aged 12 years and older.
  • In May 2022, Dermavant Sciences obtained approval from the United States Food and Drug Administration (FDA) for VTAMA (tapinarof) cream, 1%, an aryl hydrocarbon receptor agonist. This medication is indicated for the topical treatment of plaque psoriasis in adults, marking VTAMA cream as the initial and sole steroid-free topical medication in its category to gain FDA approval.
  • In June 2022, Soligenix obtained FDA Investigational New Drug (IND) Clearance for a phase II trial aimed at treating psoriasis. The trial’s anticipated completion is slated for the conclusion of 2023.

 

Psoriasis Overview

Psoriasis is a long-term inflammatory skin condition that can present with a range of clinical symptoms. It is primarily caused by a combination of immune system, environmental, and hereditary factors. This non-communicable dermatosis illness impacts around 2% of the global populace.

 

Get a Free Sample PDF Report to know more about Psoriasis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/psoriasis-pipeline-insight

 

Emerging Psoriasis Drugs Under Different Phases of Clinical Development Include:

  • FRTX-03: Fresh Tracks Therapeutics
  • IMG-008: Inmagene
  • SFA 002: SFA Therapeutics
  • PBF-1650: Palobiofarma
  • SCD-044: Sun Pharmaceutical Industries Limited
  • Rimegepant: Biohaven Pharmaceuticals, Inc.
  • PPC-06: Dr. Reddy’s
  • MP1032: MetrioPharm
  • CT-P43: Celltrion
  • ABP 654: Amgen
  • Piclidenoson: Can-Fite Biopharma

 

Psoriasis Route of Administration

Psoriasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral
  • Parenteral
  • Intravitreal
  • Subretinal
  • Topical.
  • Molecule Type

 

Psoriasis Molecule Type

Psoriasis Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type 

 

Psoriasis Pipeline Therapeutics Assessment

  • Psoriasis Assessment by Product Type
  • Psoriasis By Stage and Product Type
  • Psoriasis Assessment by Route of Administration
  • Psoriasis By Stage and Route of Administration
  • Psoriasis Assessment by Molecule Type
  • Psoriasis by Stage and Molecule Type

 

DelveInsight’s Psoriasis Report covers around 80+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Psoriasis product details are provided in the report. Download the Psoriasis pipeline report to learn more about the emerging Psoriasis therapies

 

Some of the key companies in the Psoriasis Therapeutics Market include:

Key companies developing therapies for Psoriasis are – Amgen, AbbVie, Alumis Inc, DICE Therapeutics, Inc., UCB Pharma, Janssen Research & Development, LLC, Arcutis Biotherapeutics, Inc., AnaptysBio, Inc., Sun Pharmaceutical Industries Limited, Novartis, Pfizer, Boehringer Ingelheim, KoBioLabs, Abcentra, Aclaris Therapeutics, and others.

 

Psoriasis Pipeline Analysis:

The Psoriasis pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Psoriasis with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Psoriasis Treatment.
  • Psoriasis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Psoriasis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Psoriasis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Psoriasis drugs and therapies

 

Psoriasis Pipeline Market Drivers

  • Increasing prevalence of Psoriasis across the globe, increasing combinational therapies• An increase witnessed in Biological therapy approvals for Psoriasis are some of the important factors that are fueling the Psoriasis Market.

 

Psoriasis Pipeline Market Barriers

  • However, side effects associated with the treatment, high-cost treatment and Unfavourable Reimbursement policies and other factors are creating obstacles in the Psoriasis Market growth.

 

Scope of Psoriasis Pipeline Drug Insight    

  • Coverage: Global
  • Key Psoriasis Companies: Fresh Tracks Therapeutics, Inmagene, SFA Therapeutics, Palobiofarma, Sun Pharmaceutical, Biohaven Pharmaceuticals, Inc., Dr. Reddy’s, MetrioPharm, Celltrion, Amgen, Can-Fite Biopharma, and others
  • Key Psoriasis Therapies: FRTX-03, IMG-008, SFA 002, PBF-1650, SCD-044, Rimegepant, PPC-06, MP1032, CT-P43, ABP 654, Piclidenoson, and others
  • Psoriasis Therapeutic Assessment: Psoriasis current marketed and Psoriasis emerging therapies
  • Psoriasis Market Dynamics: Psoriasis market drivers and Psoriasis market barriers 

 

Request for Sample PDF Report for Psoriasis Pipeline Assessment and clinical trials

 

Table of Contents

1. Psoriasis Report Introduction

2. Psoriasis Executive Summary

3. Psoriasis Overview

4. Psoriasis- Analytical Perspective In-depth Commercial Assessment

5. Psoriasis Pipeline Therapeutics

6. Psoriasis Late Stage Products (Phase II/III)

7. Psoriasis Mid Stage Products (Phase II)

8. Psoriasis Early Stage Products (Phase I)

9. Psoriasis Preclinical Stage Products

10. Psoriasis Therapeutics Assessment

11. Psoriasis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Psoriasis Key Companies

14. Psoriasis Key Products

15. Psoriasis Unmet Needs

16 . Psoriasis Market Drivers and Barriers

17. Psoriasis Future Perspectives and Conclusion

18. Psoriasis Analyst Views

19. Appendix

20. About DelveInsight

 

 

About DelveInsight

 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services

Related Articles

Categories